Anteris Technologies (ASX:AVR) - Hisse Senedi Fiyatı, Haberler ve Analizler

AVR Stoklara Genel Bakış

Bir yapısal kalp şirketi olan Anteris Technologies Ltd, tıbbi cihazların tasarlanması, geliştirilmesi ve ticarileştirilmesi ile ilgilenmektedir.

Şirket hakkında

AVR temel anali̇z
Kar Tanesi Skoru
Değerleme	0/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	5/6
Temettüler	0/6

Ödüller

Risk Analizi

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 24.1% oranında düşmesi öngörülüyor

Şu anda kârlı değil ve önümüzdeki 3 yıl içinde kârlı hale gelmesi beklenmiyor

Hissedarlar geçen yıl sulandırıldı

Anlamlı bir geliri yok ( A$4M )

Anteris Technologies Ltd Rakipler

EBR Systems

ASX:EBR

AU$383.9m

Cyclopharm

ASX:CYC

AU$167.3m

Respiri

ASX:RSH

AU$104.6m

Optiscan Imaging

ASX:OIL

AU$137.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti Anteris Technologies
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	AU$10.75
52 Haftanın En Yüksek Seviyesi	AU$23.93
52 Haftanın En Düşük Seviyesi	AU$9.30
Beta	0.71
11 Aylık Değişim	-11.81%
3 Aylık Değişim	-28.33%
1 Yıllık Değişim	-46.25%
33 Yıllık Değişim	25.00%
5 Yıllık Değişim	62.88%
Halka arzdan bu yana değişim	-85.86%

Son Haberler & Güncellemeler

Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why

May 22

Recent updates

Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why

May 22

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Jul 08

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

May 07

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Feb 21

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

Dec 10

Hissedar Getirileri

	AVR	AU Medical Equipment	AU Pazar
7D	-8.5%	-1.4%	-0.5%
1Y	-46.3%	17.1%	19.4%

Getiri vs. Endüstri: AVR geçen yıl % 17.1 oranında getiri sağlayan Australian Medical Equipment sektörünün gerisinde kaldı.

Getiri vs Piyasa: AVR geçen yıl % 19.4 oranında getiri sağlayan Australian Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is AVR's price volatile compared to industry and market?
AVR volatility
AVR Average Weekly Movement	8.8%
Medical Equipment Industry Average Movement	10.0%
Market Average Movement	8.7%
10% most volatile stocks in AU Market	17.8%
10% least volatile stocks in AU Market	3.6%

İstikrarlı Hisse Senedi Fiyatı: AVR son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: AVR 'nin haftalık oynaklığı ( 9% ) son bir yıldır istikrarlı seyretti.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1999	n/a	Wayne Paterson	anteristech.com

Bir yapısal kalp şirketi olan Anteris Technologies Ltd, tıbbi cihazların tasarlanması, geliştirilmesi ve ticarileştirilmesi ile ilgilenmektedir. Şirketin öncü ürün adayı, aort darlığının tedavisi için bir transkateter kalp kapağı (THV) olan DurAVR'dir. Ayrıca, ideal kapak konumlandırmasını elde etmek için kalbin doğal komissürlerinin hassas bir şekilde hizalanmasını sağlayan balonla genişletilebilir dağıtım ile DurAVR THV'nin kontrollü dağıtımını ve yerleştirilmesini sağlayan bir dağıtım sistemi olan ComASUR'u ve patentli bir kireçlenme önleyici doku teknolojisi olan ADAPT'ı sunmaktadır.

Anteris Technologies Ltd Temel Bilgiler Özeti

Anteris Technologies'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
AVR temel i̇stati̇sti̇kler
Piyasa değeri	AU$229.58m
Kazançlar(TTM)	-AU$87.90m
Gelir(TTM)	AU$3.89m

58.5x

P/S Oranı

-2.6x

F/K Oranı

AVR aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
AVR gelir tablosu (TTM)
Gelir	AU$3.89m
Gelir Maliyeti	AU$2.25m
Brüt Kâr	AU$1.63m
Diğer Giderler	AU$89.53m
Kazançlar	-AU$87.90m

Son Raporlanan Kazançlar

Jun 30, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-4.16
Brüt Marj	42.02%
Net Kâr Marjı	-2,260.86%
Borç/Özkaynak Oranı	5.3%

AVR uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

AVR Stoklara Genel Bakış

Ödüller

Risk Analizi

Anteris Technologies Ltd Rakipler

ASX:EBR

AU$383.9m

ASX:CYC

AU$167.3m

ASX:RSH

AU$104.6m

ASX:OIL

AU$137.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

Consensus revenue estimates increase by 12%, EPS downgraded

Anteris Technologies SPONSORED ADR to Be Deleted from OTC Equity

First half 2024 earnings released: AU$2.75 loss per share (vs AU$2.01 loss in 1H 2023)

Anteris Technologies Ltd has filed a Follow-on Equity Offering in the amount of AUD 30 million.

Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study

Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why

Recent updates

Consensus revenue estimates increase by 12%, EPS downgraded

Anteris Technologies SPONSORED ADR to Be Deleted from OTC Equity

First half 2024 earnings released: AU$2.75 loss per share (vs AU$2.01 loss in 1H 2023)

Anteris Technologies Ltd has filed a Follow-on Equity Offering in the amount of AUD 30 million.

Anteris Technologies and v2vmedtech Announce Concept Lock of Next Generation Mitral and Tricuspid Repair System as VClip Passes Animal Study

Shareholders May Not Be So Generous With Anteris Technologies Ltd's (ASX:AVR) CEO Compensation And Here's Why

Anteris Technologies Ltd, Annual General Meeting, May 29, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 40 million.

First half 2023 earnings released: AU$2.01 loss per share (vs AU$1.73 loss in 1H 2022)

Anteris Technologies Ltd Announces DurAVR THV Demonstrates Exceptional Results in Second Valve-in-Valve Case

Anteris Technologies Announces First Successful Implantation of Duravr™ Thv in A Valve-In-Valve Procedure

Full year 2022 earnings released: AU$3.32 loss per share (vs AU$3.09 loss in FY 2021)

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 35.000016 million.

Anteris Technologies Ltd announced that it expects to receive AUD 50 million in funding from Yorkville Advisors Global LP

Anteris Technologies Ltd Announces 12 Month Results for Anteris DurAVRTM Transcatheter Heart Valve Aortic Stenosis First in Human Study

Anteris Technologies Ltd Announces Formal Results of A Comparative Study to Investigate Aortic Flow Physiology by Cardiac MRI (cMRI) in Five Patients Who Received A DurAVR Transcatheter Aortic Valve (First- In-Human)

Anteris Technologies Ltd Announces Results Demonstrating Restoration of Normal Pre-Disease Flow

Anteris Technologies Announces Presentation of First-In-Human Data for its Novel TAVR Product, DurAVR™ at the 2022 Annual TCT Congress in Boston

First half 2022 earnings released: EPS: AU$0 (vs AU$1.58 loss in 1H 2021)

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Dr. Martin Leon, MD Joins Global Medical Advisory Board of Anteris Technologies Ltd

Anteris Technologies Ltd Provides Update on First In Human DurAVR THV Study

Anteris Announces 6 Month Follow Up of First Cohort of 5 Patients

Anteris Technologies Ltd Announces Successful Completion of Second First-In-Human Study

Anteris Technologies Ltd Announces Expansion of First in Human Trial

Anteris Technologies Ltd Appoints Dion Stub to Medical Advisory Board

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 27.6 million.

Anteris Technologies Ltd announced that it has received AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd announced that it expects to receive AUD 27.6 million in funding from Perceptive Advisors LLC

Anteris Technologies Ltd, Annual General Meeting, May 19, 2022

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) cancelled the acquisition of Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Medicus Sciences Acquisition Corp. (NasdaqCM:MSAC) (MSAC) signed a non-binding letter of intent to acquire Anteris Technologies Ltd (ASX:AVR).

Anteris Technologies Ltd Reports Successful Interim Results for the First-In-Human Trial

Anteris Technologies Ltd Reports New Patent Application for ADAPT

Independent Chairman of the Board exercised options to buy AU$58k worth of stock.

First half 2021 earnings released: AU$1.58 loss per share (vs AU$1.01 loss in 1H 2020)

Anteris Technologies Ltd announced that it has received AUD 9 million in funding

Increases to CEO Compensation Might Be Put On Hold For Now at Anteris Technologies Ltd (ASX:AVR)

Anteris Technologies Ltd Announces Successful Completion of Proof of Concept (Poc) Animal Study

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 2.327895 million.

Anteris Technologies Ltd announced that it expects to receive AUD 2.327895 million in funding

Increases to Anteris Technologies Ltd's (ASX:AVR) CEO Compensation Might Cool off for now

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

New 90-day high: AU$5.52

Does Anteris Technologies' (ASX:AVR) CEO Salary Compare Well With The Performance Of The Company?

Full year 2020 earnings released

Anteris Technologies Ltd, Annual General Meeting, May 14, 2021

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.171499 million.

New 90-day high: AU$4.30

Anteris Technologies Ltd has completed a Follow-on Equity Offering in the amount of AUD 1.068135 million.

Anteris Technologies Announces Resignation of Yanheng Wu as A Non-Executive Director on the Board

Anteris Technologies Ltd (ASX:AVR) Insiders Have Been Selling

New 90-day low: AU$3.50

Anteris Technologies Ltd Reports Interim Results from Anti-Calcification Study

Anteris Technologies Limited Announces DurAVR Valve Patient Outcomes

First half earnings released

New 90-day low - AU$4.30